Verquvo Bayer AG · Authorised · authorised 16 Jul 2021 · ATC C01
Therapeutic indication (EMA)
Treatment of symptomatic chronic heart failure
Active substance
Vericiguat
- SFDA 3
- US FDA 1
- EMA 1
- Health Canada 3
- US price lines 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Verquvo | 2.5 mg | Film-coated tablet · Oral use | 14 Blister | SAR 220.80 | NCE · Prescription | BAYER AG | Valid |
| Verquvo | 5 mg | Film-coated tablet · Oral use | 14 Blister | SAR 220.80 | NCE · Prescription | BAYER AG | Valid |
| Verquvo | 10 mg | Film-coated tablet · Oral use | 28 Blister | SAR 422.45 | NCE · Prescription | BAYER AG | Valid |
Indications — CHI Daman Drug Formulary
CONGESTIVE HEART FAILURE
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VERQUVO | 2.5MG; 5MG; 10MG | tablet · oral | MSD | Prescription | 19 Jan 2021 |
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | VERQUVO 10 MG TABLET | $22.7248 | per EA | 23 Sep 2026 |
| US NADAC | VERQUVO 2.5 MG TABLET | $22.72691 | per EA | 23 Sep 2026 |
| US NADAC | VERQUVO 5 MG TABLET | $22.72687 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 21 Jan 2026 VERQUVO — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.